Crossmark

FDA validation of surrogate endpoints in oncology: 2005–2022

Crossref DOI link: https://doi.org/10.1016/j.jcpo.2022.100364

Published Print: 2022-12

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Walia, Anushka

Haslam, Alyson

Prasad, Vinay
Funding

Funding for this research was provided by:

Arnold Ventures LLC
License Information

Text and Data Mining valid from 2022-12-01

Text and Data Mining valid from 2022-12-01

Version of Record valid from 2022-09-22
More Information

This article is maintained by: Elsevier

Article Title: FDA validation of surrogate endpoints in oncology: 2005–2022

Journal Title: Journal of Cancer Policy

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.jcpo.2022.100364

Content Type: article

Copyright: © 2022 The Authors. Published by Elsevier Ltd.